Company Overview of IRX Therapeutics, Inc.
IRX Therapeutics, Inc. develops immune therapies to treat cancer and related diseases. The company develops IRX-2, a platform technology that broadly restores the immune system by overcoming cancer-induced immune suppression. Its therapies target and restore the immune system to improve a patient’s response to cancer vaccines and targeted therapeutics. The company was founded in 1994 and is based in New York, New York.
140 West 57th Street
New York, NY 10019
Founded in 1994
Key Executives for IRX Therapeutics, Inc.
IRX Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
December 30, 2016
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact IRX Therapeutics, Inc., please visit www.irxtherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.